Entrectinib recommended for ROS1-positive advanced non-small-cell lung cancer
Evidence for entrectinib in ROS1-positive advanced NSCLC shows it is clinically effective but there are some uncertainties.
Published
Please sign in or register for FREE
Sign in to OnMedica
Or sign in via
Are you a GP or Specialist Doctor, practising in UK, looking for:
- easy-to-digest, relevant updates and educational content
- a safe-space to share and collaborate with peers?
OnMedica is for you, sign up FOR FREE now!
No comments yet.